Share Twitter LinkedIn Facebook Email Sattva Neelapu, MD, Department of Lymphoma and Myeloma, Division of Cancer Medicines, MD Anderson Cancer Center, discusses Clinical Studies Examining Axicabtagene Ciloleucel. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com
Immunotherapy Side Effects Under Scrutiny: New Data on Bone Density and T-Cell Insights AACR 3 Mins Read
Immunotherapy Revolution Unveiled: How TLS-Derived Antibodies Are Changing Cancer Treatment AACR Io 2025 AACR 4 Mins Read
AACR IO 2025: Revolutionary Insights into Desmoplastic Melanoma Treatment – Kari L Kendra, MD, PHD AACR 5 Mins Read